Type Public Operating income Revenue 2.83 billion USD (2016) | Industry Medical products Net income US$ 0.3 billion (2016) Founded 1985 | |
Traded as NASDAQ: HOLX
S&P 500 Component Key people Stephen P. MacMillan
President and CEO Stock price HOLX (NASDAQ) US$ 42.29 +0.06 (+0.14%)13 Mar, 1:09 PM GMT-4 - Disclaimer CEO Stephen P. MacMillan (9 Dec 2013–) Headquarters Bedford, Massachusetts, United States Subsidiaries Cytyc, Gen-Probe, Third Wave Technologies, Inc. | ||
Hologic, Inc. is a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, gynecological surgical, and skeletal health. It's major products include the Selenia Dimension mammography system, the Discovery and Horizon bone densitometers, the NovaSure endometrial ablation device, the ThinPrep pap test, and the Aptima, Cervista, and Prodesse diagnostic assays. While historically the Company was focused on women's health, expansion into the molecular diagnostics space has resulted in the Company's rebranding from "The Women's Health Company" to its current tagline, "The Science of Sure".
Contents
This is hologic
Recent Mergers and Acquisitions
On May 20, 2007, Hologic announced a merger (via a cash and stock transaction) with the Cytyc Corporation to create a $10 billion women's healthcare company with over $1 billion in projected annual sales.
On April 30, 2012, Hologic announced a merger with Gen-Probe for about $3.72 billion by cash.
Infiltration by Carl Icahn
In late November 2013, activist investor Carl Icahn disclosed a 12.5% stake in the company. Subsequently, the company adopted a poison pill to prevent a hostile takeover. In negotiations with the Company's board of directors, two additional directors backed by Mr. Icahn were added to the board, each managing directors of Icahn holding companies. The directors relinquished their positions in March 2016; by April 2016, Icahn's share in the Company had fallen below 5%.